drugset / Trial / NCT01143051

Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

NCT01143051

Phase 1/2 Completed 24 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), in healthy male and female adult volunteers. Safety of E004 will also be evaluated, under augmented dose conditions.

Timeline

Start
2010-01
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 1.25 mg Inhaled
Subject Epinephrine Other / unclassified 1.6 mg Inhaled
Subject Epinephrine Other / unclassified 2.2 mg Inhaled

Indications